David Silberman

This profile gathers the share dealings of David Silberman across 2 companies, led by Oramed Pharmaceuticals Inc. and Compugen Ltd. In total, 7 filings cover trades dated from 1 September 2021 to 29 July 2026.

None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.

Most recently, on 30 July 2026, the filings show a share grant in Compugen Ltd. The median gap between a trade and its publication by SEC (Form 4) is 3 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.